Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IXHL
stocks logo

IXHL

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for Incannex Healthcare Inc (IXHL.O) is -6.70, compared to its 5-year average forward P/E of -209.32. For a more detailed relative valuation and DCF analysis to assess Incannex Healthcare Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-209.32
Current PE
-6.70
Overvalued PE
207.16
Undervalued PE
-625.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.59
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.78
Undervalued EV/EBITDA
-1.97

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
24465.74
Current PS
0.00
Overvalued PS
60420.66
Undervalued PS
-11489.17
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

IXHL News & Events

Events Timeline

(ET)
2025-12-03
08:10:00
Incannex Healthcare's IHL-42X Receives FDA Fast Track Designation
select
2025-10-30 (ET)
2025-10-30
08:20:08
Incannex Shares Update with Shareholders, Outlining Priorities for 2025
select
2025-10-22 (ET)
2025-10-22
08:04:18
Nasdaq awards Incannex a 180-day extension to achieve compliance
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-03NASDAQ.COM
PinnedWhat’s Driving Incannex's Pre-market Surge?

  • FDA Fast Track Designation: Incannex Healthcare's IHL-42X, an oral fixed-dose combination for obstructive sleep apnea, has received Fast Track designation from the FDA based on positive clinical trial results.

  • Future Feedback from FDA: The company anticipates receiving detailed feedback from the FDA regarding its Phase 2 data and clinical development strategy, with plans to update stakeholders after reviewing this information.

  • Market Reaction: Following the announcement, Incannex's shares rose by 21% in pre-market trading.

  • Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.

[object Object]
Preview
9.0
12-03Newsfilter
Incannex Secures FDA Fast Track Designation for IHL-42X in OSA Treatment
  • Fast Track Designation: Incannex Healthcare's IHL-42X oral fixed-dose combination drug has received FDA Fast Track designation, supporting its potential in treating obstructive sleep apnea (OSA) and marking a significant advancement for the company in clinical stages.
  • Clinical Trial Results: In three clinical trials, IHL-42X demonstrated promising safety and efficacy, with individual reductions in the Apnea-Hypopnea Index (AHI) of up to 83%, which not only enhances patient quality of life but also establishes a strong foundation for the company's future market competitiveness.
  • Enhanced Regulatory Interaction: With the Fast Track designation, Incannex will benefit from more frequent structured interactions with the FDA to discuss clinical strategies and data requirements, which will expedite the new drug application process and increase the likelihood of market access.
  • Significant Market Potential: OSA affects millions globally, and with no approved oral pharmacotherapy currently available, the successful development of IHL-42X will fill this market gap, potentially providing substantial commercial opportunities and long-term growth for the company.
[object Object]
Preview
4.0
12-02NASDAQ.COM
Reasons to Consider Incannex Healthcare Inc. (IXHL) as a New Investment Opportunity

  • Zacks Rank Upgrade: Incannex Healthcare Inc. (IXHL) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook due to rising earnings estimates, which are crucial for stock price movements.

  • Earnings Estimate Revisions: The Zacks Consensus Estimate for Incannex has increased by 97.4% over the past three months, reflecting a strong correlation between earnings revisions and potential stock price increases.

  • Investment Potential: The Zacks rating system, which categorizes stocks based on earnings estimates, positions Incannex in the top 20% of covered stocks, suggesting it could yield market-beating returns in the near term.

  • Market Strategy: The company targets millennial and Gen Z audiences, recently generating nearly $1 billion in revenue, making it an attractive investment opportunity following a recent pullback.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Incannex Healthcare Inc (IXHL) stock price today?

The current price of IXHL is 0.4788 USD — it has increased 7.16 % in the last trading day.

arrow icon

What is Incannex Healthcare Inc (IXHL)'s business?

Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.

arrow icon

What is the price predicton of IXHL Stock?

Wall Street analysts forecast IXHL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for IXHL is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Incannex Healthcare Inc (IXHL)'s revenue for the last quarter?

Incannex Healthcare Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is Incannex Healthcare Inc (IXHL)'s earnings per share (EPS) for the last quarter?

Incannex Healthcare Inc. EPS for the last quarter amounts to -0.02 USD, decreased -93.55 % YoY.

arrow icon

What changes have occurred in the market's expectations for Incannex Healthcare Inc (IXHL)'s fundamentals?

The market is revising No Change the revenue expectations for Incannex Healthcare Inc. (IXHL) for FY2026, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -8.80%.
arrow icon

How many employees does Incannex Healthcare Inc (IXHL). have?

Incannex Healthcare Inc (IXHL) has 12 emplpoyees as of December 05 2025.

arrow icon

What is Incannex Healthcare Inc (IXHL) market cap?

Today IXHL has the market capitalization of 165.77M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free